Text Size

Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00098189
First received: December 3, 2004
Last updated: August 29, 2006
Last verified: August 2006
History of Changes
  Purpose

This extension study is being conducted to collect post-treatment safety information on patients who previously participated in the core clinical trial.


Condition Phase
Psoriasis
 Phase 2

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Retrospective
Official Title: A Follow-Up Study of Patients Previously Treated in a Core Study With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis

Resource links provided by NLM:

MedlinePlus related topics: Psoriasis
U.S. FDA Resources

Further study details as provided by Novartis:

Study Start Date: July 2004
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Consenting patients who participated in the core clinical trial
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00098189     History of Changes
Other Study ID Numbers: Ext. 1 to ASM981C201
Study First Received: December 3, 2004
Last Updated: August 29, 2006
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:
Safety, psoriasis, adverse event, SAE, extension

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Pimecrolimus
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
 Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Dermatologic Agents
Immunosuppressive Agents
Immunologic Factors
Central Nervous System Agents

ClinicalTrials.gov processed this record on May 16, 2013